Sabby Management’s BriaCell Therapeutics Corp Warrant BCTXZ Stock Holding History

Sabby Management’s Portfolio BCTXZ Stock Details BCTXZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.9K	Sell	206,753 -59,211	-22%	-$9.94K	0.06%	27
2025 Q4	$77.2K	Sell	265,964 -108,524	-29%	-$40.4K	0.11%	28
2025 Q3	$125K	Sell	374,488 -224,255	-37%	-$74.3K	0.15%	27
2025 Q2	$635K	Buy	+598,743	New	+$646K	1.15%	14

Other funds holding BCTXZ

EAM

Empery Asset Management New York $83M AUM

HCM

Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sabby Management's BCTXZ Position: Q1 2026 in Review

Sabby Management reduced its BriaCell Therapeutics Corp Warrant (BCTXZ) stake by 22% in Q1 2026, selling an estimated $9.94K and leaving 206,753 shares worth $28.9K. The position accounts for 0.06% of the portfolio, ranked #27.

Sabby Management first reported a position in BCTXZ in Q2 2025 and has held it in 4 quarters since. The position peaked at $635K in Q2 2025. 4 funds tracked by Wall St. Rank hold BCTXZ as of Q1 2026.

Sabby Management held 206,753 shares of BriaCell Therapeutics Corp Warrant worth $28.9K as of Q1 2026.
Sabby Management sold 59,211 BriaCell Therapeutics Corp Warrant shares in Q1 2026, an estimated $9.94K.
BriaCell Therapeutics Corp Warrant made up 0.06% of Sabby Management's portfolio in Q1 2026, its #27 holding.
Sabby Management first reported a position in BriaCell Therapeutics Corp Warrant in Q2 2025 and has held it in 4 quarters since.
Sabby Management's BriaCell Therapeutics Corp Warrant position peaked at $635K in Q2 2025.
4 funds tracked by Wall St. Rank held BriaCell Therapeutics Corp Warrant as of Q1 2026.

Based on Sabby Management's 13F filing for Q1 2026, filed 15 May 2026.